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2-3 years after androgen deprivation therapy, the majority of the patients progresses to castration-resistant prostate cancer (CRPC), which is the major cause of prostate cancer mortality (reviewed in Ref. 1 ). AR activity remains active in CRPC, and increased expression of AR and its splice variants, AR variants (AR-Vs), which lack the ligand-binding domain, is an important mechanism of AR reactivation in CRPC (reviewed in Refs. 1, 2 ).
The full-length AR (AR-FL) consists of three major domains, the N-terminal transactivation domain followed by the DNAbinding domain and the C-terminal ligand-binding domain. The ligand-binding domain is connected to the DNA-binding domain by a flexible hinge region (reviewed in Refs. 3, 4 ) . When activated by androgens, AR is translocated to the nucleus, forms a homodimer, and binds to regulatory regions of target genes to regulate gene expression (reviewed in Ref. 5 ). In contrast, AR-Vs lack the ligand-binding domain, but the majority contains intact N-terminal transactivation domain and DNA-binding domain and thus possesses constitutive transcriptional activity. [6] [7] [8] [9] [10] [11] [12] High expression of AR-Vs, specifically, AR-V7, AR v567es and AR-V9, has been associated with poor prognosis and short survival of CRPC patients. 8, 9, [13] [14] [15] [16] [17] Therefore, development of drugs that can target both AR-FL and AR-Vs has been an active area of research in combatting CRPC.
Raddeanin A (RA) is an oleanane-type triterpenoid saponin extracted from the root of Anemone raddeana Regel, a traditional
Chinese medicinal herb used to treat rheumatism and arthritis in ancient China. 18 Preclinical studies have indicated the antitumour activity of RA against gastric cancer, colorectal cancer, breast cancer, liver cancer, choriocarcinoma, glioblastoma and osteosarcoma. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In the present study, we sought to investigate the anticancer effect of RA in prostate cancer. We found that it could suppress the activity of both AR-FL and AR-Vs to inhibit the growth of prostate cancer cells at an in vivo achievable concentration. Cell growth was assessed by the sulforhodamine (SRB) assay as described, 31 and the SRB assay was performed at least three times in six replicates. 
| Western blot analysis

| Quantitative reverse transcription-PCR
The Quantitative reverse transcription-PCR (qRT-PCR) analysis was performed as described. 35 The TaqMan performed at least three times in triplicate, and AR, PSA and UBE2C levels were normalized by 36B4 levels.
| Statistical analysis
The Student's two-tailed t test was used to determine the mean differences between two groups. P < 0.05 is considered significant.
Data are presented as mean ± SD from at least three independent experiments.
| RE SULTS
| RA inhibits the growth of prostate cancer cells
We first assessed the effect of RA on the growth of CRPC cells by the SRB assay. The assay was conducted in the presence or absence of 1 nmol/L R1881, a synthetic androgen, for the AR-expressing 22Rv1, C4-2, C4-2B and LNCaP95 cells and in androgen-deprived condition for the AR-null PC-3 and DU145 cells. The doses of RA that we tested were from 0 to 6 μmol/L. This was because RA can reach a maximum plasma concentration of ~4.5 μmol/L in rats after a single intraperitoneal administration at 0.75 mg/kg. 29 As presented in Figure 1A , B, RA inhibited the growth of all AR-positive cells in a dose-and/or time-dependent manner. The inhibition appears to be independent of androgen. In contrast, no growth inhibition was observed in the AR-null cells ( Figure 1C ). These results suggested that RA-induced growth inhibition in CRPC cells might be AR dependent but androgen independent.
| RA suppresses AR signalling
We therefore investigated the effect of RA on AR transcriptional activity by reporter gene assay. We first transfected C4-2 and 22Rv1 Figure 2C and D) . Importantly, the down-regulation was evident prior to significant changes in cell growth, indicating that the effect was unlikely secondary to growth inhibition. Collectively, these data support the ability of RA to inhibit AR-FL and AR-V transactivation.
| RA down-regulates AR protein
To understand the mechanism by which RA inhibits AR transactivation, we examined AR protein levels after RA treatment. C4-2 and 
| RA induces proteasome degradation of AR
To determine whether the decrease in AR proteins was due to increased protein degradation, we treated C4-2 and 22Rv1 cells with cycloheximide to stop protein synthesis and monitored the decay rates of AR-FL and AR-V proteins in response to RA treatment either in the presence or absence of androgen. As shown in Figure 4 , in both conditions, RA increased the decay rates of AR-FL and AR-V proteins. It has been described that proteasome-mediated pathway is the main machinery regulating AR protein degradation. [36] [37] [38] To determine the role of proteasome in RA-induced AR degradation,
we assessed the effect of the proteasome inhibitor MG132 on RA down-regulation of AR proteins. As shown in Figure 5 , the addition of MG132 greatly attenuated RA down-regulation of AR, restoring the levels of AR-FL and AR-V proteins to almost the control level.
Collectively, these data indicated that inducing proteasome-mediated degradation of AR-FL and AR-V proteins is a mechanism by which RA decreases their expression.
| RA suppresses the transcription of the AR gene
To investigate whether RA could modulate AR at the RNA level in addition to inducing AR protein degradation, we measured AR-FL and AR-V7 mRNA levels by qRT-PCR. Interestingly, RA reduced the levels of both AR-FL and -V7 mRNA ( Figure 6A and B) . Moreover, RA treatment led to a significant inhibition of the activity of a 1.7 kb proximal AR promoter ( Figure 6C ). Collectively, these findings indicated that RA downregulates AR at both transcriptional and post-translational levels.
| RA enhances the growth inhibitory efficacy of docetaxel
As the first-line chemotherapy for patients with metastatic CRPC, docetaxel has been shown to inhibit nuclear translocation and transcriptional activity of AR-FL. [39] [40] [41] [42] [43] [44] [45] However, AR-Vs, especially AR-V7, are resistant to docetaxel modulation, and this has been proposed to be a mechanism of docetaxel resistance. 43, 45, 46 Because of the ability of RA to down-regulate AR-V expression and activity as well as its ability to inhibit AR-FL through a different mechanism from docetaxel, we hypothesized that RA may denotes synergism, additivity, or antagonism, respectively. All the combinations produced a combination index value of less than 1, suggesting a synergy between RA and docetaxel in inhibiting cell growth ( Figure 7A ). The synergy was more pronounced in androgen-deprived condition compared to the androgen-present condition. Shown in Figure 7B is the combination that produced the best synergy. Cell growth was more significantly inhibited by the combination treatment than by single-agent treatments. These data provided support for the potential of using RA to enhance docetaxel efficacy in CRPC.
| D ISCUSS I ON
The present study represents the first to characterize the activity of RA in prostate cancer, particularly CRPC. We showed that RA in- The AR-FL protein is known to suppress the transcription of the AR gene, producing a negative feedback on the expression of AR mRNA. 47 Consequently, RA-mediated decrease of AR protein would be expected to lead to upregulated AR mRNA expression.
Nevertheless, our results showed that RA could inhibit the transcription of the AR gene and reduce AR-FL and AR-V mRNA levels,
indicating that RA could turn on a mechanism counteracting AR negative auto-regulation. This is significant because it could lead to a sustained down-regulation of AR-FL and AR-Vs, and further study is needed to identify the mechanism.
While supporting the anticancer activity of RA that has been indicated in other cancer types, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] These compounds may also have the potential to improve the efficacy of the first-line chemotherapy for prostate cancer, docetaxel.
Androgen-induced translocation of AR-FL to the nucleus, which is required for the transcriptional activity of AR-FL, has been reported to use a microtubule-facilitated pathway. 39, 40, 43, 46 By stabilizing microtubules, docetaxel has been shown to attenuate AR-FL nuclear import. [39] [40] [41] [42] [43] On the other hand, the nuclear localization of AR-Vs, especially AR-V7, is independent of microtubule and thus insensitive to docetaxel inhibition. 43, 46 As a result, AR-V expression has been proposed to be a mechanism of docetaxel resistance. 43, 46 Here, we showed that, by down-regulating AR-FL and AR-V expression and activities, RA enhances the growth inhibitory efficacy of docetaxel in CRPC cells. RA has a low bioavailability if administered orally. 28, 30 With a single oral administration of 1.5 mg/kg RA to mice and 2 mg/ kg RA to rats, the maximum plasma concentration can only reach 12-13 nmol/L, and the majority of RA is distributed to the intestinal tract, particularly the colon and caecum. 28, 30 However, a maximum plasma concentration of ~30 or 3 μmol/L can be reached after intravenous or intraperitoneal administration of rats with 0.75 mg/kg RA, and the concentration can sustain in the μmol/L range for 6-8 hours. 29, 30 Therefore, determining the best route of RA administration and the best sequences of the combination treatment is needed. Taken together, the findings from the current study provide a rationale for further developing RA or its analogue for intervention of CRPC.
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